The adenovirus (Ad) E1A gene exerts an antitumor effect and can induce sensitivity to treatment with DNA-damaging agents. In contrast, the Ad 19-kDa E1B protein inhibits E1A-mediated apoptosis and the 55-kDa E1B inactivates the p53 protein. In this paper, we study the in vitro and in vivo effects of a 19-kDa and 55-kDa E1B-defective Ad in several malignant human tumor cell lines.
M alignant tumors are characterized by the great heterogeneity of cell types, pathological features, and clinical behaviors. [1] [2] [3] Malignant cells carry multiple genetic alterations that accumulate during the process of carcinogenesis, leading to more "malignant" or "aggressive" phenotypes. 4 -7 Many oncogenic alterations are still unknown, and it is currently accepted that, except for some lymphoproliferative and leukemic diseases and specific childhood round-cell tumors, there are no specific oncogenic alterations. 8 -10 Based on the knowledge of the molecular biology of malignant cells, numerous approaches are being undertaken in the development of new therapeutic protocols. 10 -14 Most of these approaches have focused on the replacement of genes, such as p53, that have undergone mutation or deletion. 14 -18 Nevertheless, because of the amazing variety of genes involved in cell transformation, other studies have focused on the use of genes that induce cell death or increase cell susceptibility to apoptosis after exposure to DNA-damaging agents, regardless of the multiple genetic alterations activated in the cells. 4,19 -21 One of these genes is the adenovirus (Ad) E1A gene. Early region 1A of human Ad type 5 (Ad5) encodes two major proteins of 289R and 243R, synthesized after infection, that have myriad cellular effects. These proteins provide an optimal environment for viral replication and can activate and repress the transcription of multiple genes (reviewed in Refs. 22, 23, and 24) . Most of their effects are modulated by binding to different cellular proteins, including the cyclic adenosine monophosphate-response-element-binding protein and a related protein p300, pRb and related proteins p130 and p107, p60/cyclin A, p33cdk2, BS69, and CtBB. Thus, Ad5 E1A can repress HER-2/neu, p27/kip1, p21/waf1/ cip1, p15/INK41, and other genes. [25] [26] [27] [28] [29] Interestingly, the E1A gene appears to have a dual and paradoxical effect on cells. E1A gene can activate DNA synthesis and cell proliferation when cells are growing in optimal conditions or can drive cells rapidly to apoptosis in sera-free medium or after DNA damage. These opposing processes involved in cell proliferation and death can be generalized to virtually all other promoters of cell proliferation such as c-myc, the G1 progression transcription factor E2F1, and the Cdc25a phosphatase. 30 -32 The antitumor effect of Ad E1A was initially described by Frisch, 33 who observed it in malignant cells transfected by E1A-12S. Recently, this effect has also been obtained after the injection of retrovirus E1A producer cells into the tumors. 34 Some authors have associated the antitumor effect of Ad E1A with the down-regulation of the transcription of HER-2/neu 35, 36 or the conversion of tumor cells into an epithelial phenotype. 37 In addition, in many cases, E1A expression prevents malignant cells from metastasizing. 38 We reported previously that the Ad E1A gene induces an increased sensitivity to DNA-damaging agents in murine keratinocytes and multiple carcinoma cell lines, regardless of p53 status and other genetic alterations of the malignant cells. 21,39 -41 Moreover, we affirmed that in several E1A mutant-expressing cells, sensitivity to DNAdamaging agents requires binding to p60 pRb and p300 cellular proteins independent of the level of expression of the p53 protein. We postulated that other cellular mechanisms in addition to p53 must be involved in the sensitization of cells to the DNA-damaging agents induced by the wild-type (wt) E1A gene. 40 Recently, we have shown that the Ad E1A gene decreases the tumorigenicity of carcinoma cells in cell lines with a constitutive E1A expression and after intratumoral (i.t.) injection of retrovirus-E1A producer cells. 34 Other studies with recombinant Ads have shown that E1B-defective Ad5 also induces p53-dependent and -independent apoptosis, and that the expression of other Ad early gene products, such as an E4 product, may be essential for E1A-induced, p53-independent apoptosis. 42 Interestingly, 55-kDa E1B-defective Ad5 was reported to replicate selectively in p53-deficient human tumor cells 43 and, more recently, the same vector ONYX-015 was observed to be capable of destroying numerous carcinoma cell lines with either a mutated or normal p53 gene. 44 These promising approaches to cancer gene therapy are already undergoing clinical trials.
Recently, we reported that infection with Ads lacking both E1B genes (19-kDa E1B and 55-kDa E1B) could be a more efficient method of inducing lethality acting on malignant cells. 45 Both E1B proteins encoded by the E1B region seem to be involved in controlling most of the effects mediated by the E1A gene. In fact, the 19-kDa E1B gene may prevent the premature death of Ad-infected cells and inhibit the apoptotic pathways induced by expression of the Ad E1A protein, whereas the 55-kDa E1B protein leads to the stabilization of p53 and may inhibit the transcriptional activation potential of p53. 46 We hypothesized that Ads lacking expression of the 19-kDa and 55-kDa E1B proteins and having inherent E1A function could combine the antitumor effects of Ad E1A protein and the selective replication of E1B-defective Ads. We show here that the mutant Ad H5 dL118 exerts a marked cytopathic effect on several malignant human cell lines and a partial reduction of tumorigenicity in vivo. Moreover, we show that this mutant Ad can enhance chemosensitivity to DNA-damaging agents in vitro and in vivo.
MATERIALS AND METHODS

Cell lines
Several cell lines derived from the most common human tumors were studied, including HeLa cells (from cervical carcinoma carrying human papilloma virus, with wt but inactivated p53), A431 cells (epidermoid carcinoma; mutated p53), HT29 cells (colon adenocarcinoma; mutated p53), MCF7 cells (breast adenocarcinoma; wt p53), Saos-2 cells (osteosarcoma; absence of p53), and three uveal melanoma cell lines: MKTBr (mutated p53), OCM1 (mutated p53), and Sp6 (wt p53). The cells were grown in Dulbecco's modified Eagle's medium (Life Technologies, Grand Island, NY) supplemented with 10% fetal calf sera and antibiotics, with the exception of the melanoma cell lines, which grew in RPMI 1640 medium.
As nontumorigenic cells, the fibroblastic cell lines Hs67 and CCD-45SK, uveal melanocytes UW3, lymphocytes (from a donor), and the Vero cell line were used. Moreover, a spontaneously transformed set of Hs67 fibroblasts was analyzed (wt 53).
Viruses
wt Ad5 (wt 300) and a recombinant, replication-deficient Ad H5 dL118 (provided by Dr. Ginsberg, National Institutes of Health, Rockville, MD) were employed. H5 dL118 contains a deletion in the E1B region and does not synthesize the 19-kDa or 55-kDa E1B proteins. 47 Both wt 300 and H5 dL118 carry a small deletion in the E3 region. Ads were grown on the human embryonic kidney cell line 293. 48, 49 Viruses were purified, titrated by plaque assay, and stored in 10% glycerol/phosphatebuffered saline (PBS) at Ϫ70°C as described previously. 35, 48 The 293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 0.01 M L-glutamine, antibiotics, and 10% fetal calf sera. During viral infection, 5% horse sera was added.
Replication assays
Two different methods were used to analyze the replication efficiency of H5 dL118 and wt Ads in the A431 and HeLa cells. First, virus supernatants were tested at serial dilutions to infect the 293 cells (plaque assays), as described previously. 49 Second, we compared the replication of the viruses in both 293 cells and the carcinoma cell lines A431 and MCF7 (that most sensitive and that most resistant to infection with these Ads, respectively). We infected them at a multiplicity of infection (MOI) of 20 per cell and obtained lysates at 1, 2, 3, and 5 days postinfection by three cycles of freezing and thawing. We subsequently infected 293 cells at 80% confluency with serial dilutions of the lysates obtained from 293, A431, and MCF7 cell lines. At 48 hours postinfection, the wells were fixed in glutaraldehyde and stained by the crystal violet method.
Sensitivity to cisplatin and radiotherapy
Cisplatin (CDDP, Bristol-Myers, Syracuse, NY) was used at doses ranging from 0.01 to 10 mg/mL. All dilutions were performed in PBS. In irradiation assays, cells were ␥-irradiated with a 60 Co source at a skin surface distance of 57 cm and a dose rate of 238 cGy/min.
A total of 4 ϫ 10 4 cells/well were plated in 24-multiwell culture plates; drugs were added 48 hours after plating. Cell viability was measured after different times of exposure to CDDP or doxorubicin. Cell density was evaluated by the crystal violet method. 50 Briefly, cells were fixed with 1% glutaraldehyde for 10 minutes, washed twice in PBS, and stained with 1.5 mL of 0.1% crystal violet solution for 30 minutes. Wells were rinsed in a beaker with a slow stream of distilled water until the dye was washed off and left to dry overnight. Absorbance was read at 590 nm by dye uptake in 10% acetic acid. For 7-day experiments, 5 ϫ 10 3 cells/well were plated 24 hours prior to being irradiated at doses ranging from 1 to 8 Gy.
Immunohistochemistry for Ad protein expression
For immunohistochemistry, the different cell lines were placed on glass slides, as described previously. The antibody (Ab) M73 (anti-E1A, Oncogene Science, Uniondale, NY) and monoclonal Ab 805 (anti-Ad capsid, Chemicon International, Temecula, Calif) were applied at dilutions of 1/50 and 1/100, respectively. The cells were incubated for 1 hour with the primary Ab, followed by a biotinylated goat anti-mouse secondary Ab and the streptavidin-horseradish peroxidase conjugate. Diaminobenzidine was used as the chromogen, and slides were counterstained with hematoxylin.
Western blot analysis of Ad E1A protein expression
Cells were collected in a buffer (50 mM tris(hydroxymethyl) aminomethane/HCl, 150 mM NaCl, 0.1% sodium deoxycholate, and 1% Triton X-100) with protease inhibitors (10 mg/mL aprotinin and 100 mM phenylmethylsulfonyl fluoride). The protein content was determined by the Bradford assay (Bio-Rad, Richmond, Calif). A total of 50 g of protein was dissolved in the sample buffer, heated at 90°C for 5 minutes, and analyzed by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. For immunoblotting, we used the M73 Ab (Oncogene Science) to detect E1A gene products. Blots were revealed by the enhanced chemiluminescence method (Amersham, Arlington Heights, Ill). Blots were analyzed using National Institutes of Health Image 1.5 software.
Analysis of caspases
Preparation of cytosols. After infection with 20 plaque-forming units (PFU) of wt and mutant H5 dL118 Ads, cells were allowed to sediment at 250 ϫ g for 10 minutes, washed twice in PBS, and resuspended in extraction buffer (50 mM tris(hydroxymethyl)aminomethane/HCl (pH 7.6), 150 mM NaCl, 0.5 mM ethylenediaminetetraacetic acid, 10 mM NaH 2 PO 4 , 10 mM Na 2 HPO 4 , and 1% Nonidet P-40, supplemented immediately before use with 0.4 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 10 g mL-1 aprotinin, and 10 g mL-1 leupeptin). After a 30-minute incubation on ice, the cell lysate was centrifuged at 20,000 ϫ g for 30 minutes, and the supernatant was used as cytosolic extract.
Fluorogenic assays. The cytosolic extract (aliquots containing 1 mg mL-1 of cytosolic protein estimated by the bicinchoninic acid method 51 ) was diluted five times with the assay buffer (25
sucrose, 10 mM dithiothreitol, and 0.1 mg mL-1 ovalbumin) and incubated at 37°C for 2 hours with a 10-M concentration of the fluorescent substrate (AC-YVAD-7-amino-4-methylcoumarin (AMC), AC-DEVD-AMC, and AC-VEID-AMC for interleukin-1␤-converting enzyme (ICE)-, CPP32-, and Mch2-like activity, respectively). The reaction was stopped by the addition of high performance liquid chromatography buffer (water/acetonitrile, 75/25; 0.1% trifluoroacetic acid). Cleaved substrate fluorescence was determined by C18 reverse-phase high performance liquid chromatography using fluorescence detection (338 nm excitation and 455 nm emission). Control experiments (data not shown) confirmed that the release of substrate was linear with time and with protein concentration under the conditions specified.
Tumorigenicity assays
HeLa and A431 cells were infected with H5 dL118 and wt 300 at an MOI of 20. An equal amount of cells was treated with medium as a control. After 30 minutes of infection, the treated cells were harvested and rinsed with PBS. For each injection, 1 ϫ 10 6 cells in a volume of 100 mL were injected subcutaneously into nude (nu/nu) mice aged 4 -5 weeks. Five mice were used for each treatment; they were examined every other day with calipers to determine two perpendicular diameters. In other experiments, 1 ϫ 10 6 HeLa and A431 cells were mixed in vitro with 1 ϫ 10 6 293 producer cells that had been infected previously with both Ads.
Inhibition of tumor growth in vivo
When the tumors reached a diameter of 2-3 mm, 100 L of H5 dL118 (2 ϫ 10 11 PFU) or of PBS alone were injected i.t. and every other day for a total of three times. Mice were irradiated on the following days to the injection of Ads. The tumors were measured every other day with calipers.
RESULTS
Immunodetection of viral proteins
Immunohistochemistry with anti-E1A (M73) and anti-Ad capsid (monoclonal Ab 805) Abs revealed viral protein expression by 24 hours postinfection. The cells infected with the wt Ad at an MOI of 20 were positive for both Abs, with an intensity similar to those infected with mutant H5 dL118.
To correlate the cellular effects with E1A protein expression, we performed Western blot analysis of several lysates in the days immediately following infection. As shown in Figures 1 and 2 , marked E1A protein expression was detected at 48 hours after infection with the recombinant H5 dL118 Ad. Nevertheless, the E1A protein could be detected for a period of 7 days (data not shown). Because the effects of these Ads on malignant cells could be due both to viral replication and cytolytic effects and to E1A protein expression, we analyzed the level of E1A protein in nontumorigenic human cells (Fig 2) . As can be seen, the Ad infected the cells properly, with a high content of E1A protein at 24 -48 hours postinfection.
Cell viability after Ad infection
Primary, nonimmortalized human fibroblasts and lymphocytes and the monkey Vero cell line were resistant to cytolysis with the Ad H5 dL118 after 3 days of exposure at an MOI of 20. Conversely, most of the malignant cells showed a marked decrease in cell viability at 48 hours postinfection. As shown in Figures 3 and 4 , only the breast carcinoma MCF7 and the uveal melanoma cell lines were more resistant, although less so than the control cells. Interestingly, the spontaneously transformed fibroblastic cell line Hs67 (wt p53) showed no differences in cell viability for the first 5 days, but presented a marked decrease thereafter.
Cell viability differed very significantly in the malignant cells depending upon whether they had been exposed to wt Ad or H5 dL118 Ad infection. At similar MOIs, the cellular effects and the decrease in cell viability were significantly more marked in the cells infected with mutant H5 dL118 than in the cells infected with the wt Ad over the first days after infection. As shown in Figure 3 , after infection with the Ad H5 dL118, the percentage of cell density was 2-10 times less than in the same cells infected with wt Ads. This cytotoxic effect of the recombinant H5 dL118 Ad was also detected in human malignant cells with wt p53 (exons 5-9), especially in HeLa cells and uveal melanoma Sp6 cells. Moreover, the melanocytic cell lines Sp6 and OCM1 infected with H5 dL118 showed an increased sensitivity to ␥-irradiation (Fig 4) .
Viral replication
To determine whether the cellular effects were due to viral replication, we studied the viral replication by an indirect method, 35 taking diluted concentrations of the medium and cell lysates of the infected human malignant and 293 cells several days after infection; next, we added the medium to noninfected 293 cells. As shown in Figure 5 , the cytopathic effect and the decrease in cell viability were rapidly detected at 3 days after infection with the supernatant of the previously infected A431 (very sensitive to H5 dL118) and MCF7 (more resistant to H5 dL118) cell lines. These results confirm the fact that H5 dL118 replicates very actively in the carcinoma cell line A431 and ϳ100 times less efficiently in MCF7 cells. To study whether the titer of the H5 dL118 Ad increases in infected human cells, we took supernatants at 24 hours, 48 hours, and 5 days and compared them with a known virus titer of the H5 dL118. In these experiments, we detected a significant increase of the titer of H5 dL118 in A431-infected cells, with titers ranging from 1.5 ϫ 10 5 at 24 hours postinfection to 1.5 ϫ 10 8 after 5 days postinfection. Conversely, we did not observe an increase of the titer in the supernatants taken from MCF7 infected cells. In addition, infection with H5 dL118 Ads at MOIs of 0.1, 1, and 10 showed that malignant cells were killed much more efficiently with lower MOIs per cell than nontumorigenic cells (data not shown).
Inhibition of tumorigenicity
To examine whether the H5 dL118 virus could inhibit the tumorigenicity of the human malignant cell lines, nude mice were injected subcutaneously with A431, HeLa, and HT29 cells in two different experiments to initiate tumor formation. First, we injected the malignant cells (2 ϫ 10 6 cells) that had been infected with wt or H5 dL118 Ads at an MOI of 20 for 45 minutes. Cells treated with medium alone were used as noninfected controls. Interestingly, none of the cell lines infected with both the wt and mutant H5 dL118 developed tumors. Moreover, we injected A431 concomitantly with the 293 producer cells infected previously with the Ads. We obtained similar results as before, with no tumor formation. Conversely, the injection of A431 and noninfected 293 cells resulted in tumors as large as those produced in the controls (data not shown).
Inhibition of tumor growth in vivo
To address the feasibility of using H5 dL118 virus infection in the treatment of established tumors, we injected H5 dL118 i.t. when the tumors reached a diameter of 4 mm. Three different experiments were performed. First, mice with HT29 and A431 tumors received a single injection of Ad or PBS; it was observed that the application of H5 dL118 produced a decrease in tumorigenicity for the first 5-10 days postinjection, after which tumor growth resumed. In another experiment, when tumors had a diameter of 3-4 mm, Ad H5 dL118 or PBS was injected i.t. on 5 consecutive days. In the mice injected with H5 dL118, some tumors partially regressed; most showed no increase in size over the following 4 weeks. Third, HeLa tumors were injected with three injections of H5 dL118 Ad every other day or with PBS in the control animals, and mice were ␥ irradiated. As shown in Figure 6 , the injection of H5 dL118 induced a decrease in tumorigenicity that was enhanced by the additional ␥-irradiation of the tumors (Fig 6) .
Detection of apoptosis
To determine whether the decrease in cell viability observed in malignant cells could be related to the induction of apoptosis, we studied the treated cells by flow cytometry, agarose gel electrophoresis, and fluorogenic assays to detect the activation of caspases. In agarose gels, we were unable to detect the presence of DNA ladder formation in the various cell lines at 2, 3, 4, 5, and 7 days postinfection (data not shown). In the flow cytometry studies performed in the A431, MCF7, and melanoma cell lines (infected at an MOI of 20), only a small percentage of cells (ranging from 10% to 25%) prior to the G 1 peak were observed after 72 hours postinfection (data not shown).
The activation of the caspases ICE, CPP32, and Mch2 was analyzed by fluorogenic assays. As shown in Figure  7 , we could only detect activation of the caspase CPP32 for the first 3 days in cells infected with mutant H5 dL118.
DISCUSSION
In this paper, we show that Ads with deletion of the 19-kDa and 55-kDa E1B genes induce a striking cytotoxic effect on human malignant cell lines in vitro and increase the response to ␥-irradiation with a reduction of tumor size. Moreover, we show that carcinoma cell lines infected previously with mutant Ad H5 dL118 are nontumorigenic, and that an i.t. injection of Ads partially decreases the tumorigenicity.
Based on previous studies where we and others 21, 33, 34, 38, 40, 41 demonstrated that retrovirus-mediated gene transfer of the Ad E1A gene induces a significant decrease in tumorigenicity and a marked susceptibility to DNA-damaging agents, we hypothesized that Ads with expression of the E1A protein and in which both the 19-kDa and the 55-kDa E1B proteins had been deleted would be capable of exerting a more significant effect on cell viability than the E1A expression mediated by retroviruses. Both proteins encoded by the E1B region seem to be involved in controlling some of the effects of the E1A protein, including E1A-induced apoptosis. 24, [52] [53] [54] By infection with mutant H5 dL118, we obtained high levels of the E1A protein in both malignant and normal human cells, but only transformed cells showed a marked cytopathic effect during the first 3 days postinfection, whereas the normal cells kept growing for Ͼ10 days.
These results raise some interesting questions and observations. First, the application of the E1B-defective Ad, with an absence of both E1B proteins, also produces a marked and selective antitumor effect similar to that reported previously with the 55-kDa E1B-defective Ad ONYX-015. 44 The cytotoxic effects are also observed predominantly in malignant cells with a mutated or wt p53 gene. 44 Interestingly, the cytopathic effect of the vector ONYX-015 was similar to the wt Ads, whereas the mutant H5 dL118 kills the malignant cells much faster than the wt Ad. This "faster" and selective effect could be related to a more efficient Ad replication, to the absence of the 19-kDa E1B protein, which is a very potent inhibitor of apoptosis, 54, 55 and/or to E1A protein expression in the cells.
Second, infection with H5 dL118 increases the in vitro and in vivo cellular response to ␥-irradiation in some cell lines. This effect may be related to E1A expression, as reported previously. 21, 39, 41 Third, we detected a scarce apoptotic cell population and moderate activation of the caspase CPP32 in H5 dL118-infected cells by flow cytometry analyses and fluorogenic assays. These results would be similar to those pointed out previously by Zhang et al. 35 It is known that Ad infection can induce both apoptotic and necrotic types of cell death, depending upon the cell type. 56 Moreover, Ad-induced cell death can occur independently of p53 expression, 42 and E1A products can induce p53-independent and p53-dependent apoptosis. 21, 40, 52, 55 Previous reports indicated that p53-independent apoptotic cell death was induced only by the 289R E1A protein, and that an E4 product was essential for E1A-induced p53-independent apoptosis. 42 Therefore, after infection with Ad H5 dL118, we cannot conclude that cell death is mediated predominantly by apoptotic or necrotic mechanisms. It seems that cells may die by either or both pathways, because we could detect a small population of apoptotic cells by flow cytometry and electron microscopy as well as a moderate activation of caspase CPP32.
The 19-kDa E1B protein may block both types of cell death and, in fact, may facilitate virus multiplicity by preventing premature cell death. Interestingly, it has been shown that Ad type 2 19-kDa deletion mutants can induce a necrotic type of cell death in permissive human cells and an apoptotic type in nonpermissive cells with a much lower production of Ads. 56 In fact, we detected only a small population of apoptotic cells after infection with 10 -20 PFU of the mutant H5 dL118 Ad and no apoptosis whatsoever at high Ad concentrations. Importantly, previous reports 56 indicated that infection with the 19-kDa-deleted Ad provoked a marked decrease in cell viability in vitro that was almost as prominent as that observed with the 19-kDa/55-kDa mutant Ad H5 dL118. 56 These results indicate that the cellular effect of the double-mutant H5 dL118 is not only related to the selective replication of this vector in p53-deficient cells, as proposed for the 55-kDa mutant Ad ONYX-015. In fact, a comparison of the cell viability and the viral replication of the 19-kDa/55-kDa mutant H5 dL118 with those of the 19-kDa mutant Ad and of the 55-kDa mutant Ad ONYX-015 seems to suggest that absence of the 19-kDa E1B protein may be related to the strikingly decreased cell viability of malignant cells and to the random DNA fragmentation in human cell lines. Nevertheless, the higher cytotoxicity of H5 dL118 when compared with that reported for the 19-kDa mutant Ad may be due to the concomitant absence of the 55-kDa E1B protein. It has been proposed recently that the pathways driving cells to apoptosis and necrosis are not as independent as previously supposed. 57 The availability of apoptogenic proteases, activated following mitochondrial permeability transition, could dictate the mode of cell death. 58 In fact, after infection with the completely E1B-defective Ad H5 dL118, we could only detect activation of the CPP32 caspase and mixed cell populations of necrotic and apoptotic cells. The fact that we infected proliferating cells could explain the absence of E1A-mediated apoptosis. 59 The fact that infection with defective Ads sensitizes malignant cells to ␥-irradiation is the most relevant result obtained in vivo. This result may be due to the expression of the E1A protein and the absence of the 19-kDa E1B protein, as reported previously in retroviral-mediated systems. The enhanced response to radiotherapy could be the basis for future clinical trials, combining injection of these completely E1B-defective Ads and ␥-irradiation. Importantly, no significant side effects could be detected in mice after repeated injections of mutant H5 dL118.
The prospects for gene therapy with defective Ads are controversial. Most of the clinical trials in progress focus on the application of E1-Ad carrying the wt p53 gene, the p16 gene, or suicide genes. 10, 12, 14 An overexpression of p53 may induce apoptosis in carcinomas with mutated or wt p53 protein, and preliminary clinical data point to an in vivo antitumor effect of these Ads. 14, 18 With the completely E1B-defective Ads, which combine the selective viral replication of the 55-kDa E1B Ad, the potent cytopathic effect of the 19-kDa mutant Ad, and high-level E1A protein expression, a significant antitumor response may be expected in human tumors. The concomitant ␥-irradiation of those tumors may be a novel approach in the treatment of human cancers.
